Today: 3 June 2026
Browse Category

NASDAQ:QNCX 10 February 2026 - 18 May 2026

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing

Quince Therapeutics was last quoted at $1.15 before Monday’s Nasdaq open after Nantahala Capital Management disclosed 7.52% beneficial ownership. The company’s latest filing reported no current product candidates and raised substantial doubt about its ability to continue as a going concern. Quince is seeking shareholder approval for another reverse stock split at its June 11 meeting. The company remains out of compliance with Nasdaq’s $50 million market value rule.
18 May 2026
·
Upcoming Stock Splits This Week: Nasdaq Reverse Splits Pile Up as Booking, Powell and Pashupati Stand Apart

Upcoming Stock Splits This Week: Nasdaq Reverse Splits Pile Up as Booking, Powell and Pashupati Stand Apart

NextPlat, MultiSensor AI, Cenntro, and Quince Therapeutics will begin trading Monday on a reverse-split basis, with ratios ranging from 1-for-10 to 1-for-60. Several other Nasdaq-listed firms, including Huachen AI Parking and Akanda, are also set for reverse splits. Last week saw forward splits from Booking Holdings and Powell Industries. Cenntro and Quince both disclosed ongoing Nasdaq compliance concerns.
13 April 2026
·······
Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive

Quince Therapeutics (QNCX) stock price jumps in premarket as strategic review keeps deal talk alive

Quince Therapeutics shares jumped about 48% to 78 cents in premarket trading Wednesday after the company hired LifeSci Capital to explore strategic alternatives and liability restructuring. The move follows a failed late-stage drug trial and the resignation of five board directors. The stock surged from 13 cents Monday to 52.8 cents Tuesday on heavy volume. Investors await further disclosures or a timeline for next steps.
11 February 2026
·
Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move

Quince Therapeutics (QNCX) stock slides before the bell after LifeSci Capital deal review move

Quince Therapeutics shares dropped 6.6% to $0.13 in premarket trading after the company hired LifeSci Capital to advise on strategic alternatives and liability restructuring. The move follows a failed Phase 3 trial in late January and the resignation of five directors. Quince said it will not provide further updates unless its board approves a specific action.
10 February 2026
·

Latest articles

NuScale shares rise 5% as investors watch small-nuclear sector test

NuScale shares gain 8% ahead of market; SMR project faces another milestone

3 June 2026
NuScale surged 8.2% to $13.95 on nearly 60 million shares traded after adding ex-NRC chairman Dale Klein and mining exec Stuart Harshaw to its board, as investors bet on small modular reactors despite Q1 revenue plunging to $565,000 from $13.4 million and key projects still awaiting financing or contracts.
Partners Group Drops 17% After Cap on $8.6 Billion Fund Outflows

Partners Group Drops 17% After Cap on $8.6 Billion Fund Outflows

3 June 2026
Partners Group shares plunged 16% to CHF 687.30 after capping withdrawals from its $8.6 billion Global Value SICAV fund, as redemption requests hit 9.8% of net asset value, nearly double the 5% quarterly limit; the move triggered sharp declines in peers EQT, CVC, and Bridgepoint, and marked the worst day on record for Partners Group shares, now down about 30% for the year.
Idaho Power Pushes for Two New Gas Plants; Customer Timeline Starts

Idaho Power Pushes for Two New Gas Plants; Customer Timeline Starts

3 June 2026
Idaho Power seeks state approval for two new gas plants to address projected capacity deficits of 236 MW in 2029 and 352 MW in 2030, with no immediate rate hike proposed; parent IDACORP says the case is pending, and large customers plus clean-energy groups have joined the proceeding as intervenors.
Victoria’s Secret Stock Posts Record Session, Looks to What’s Next

Victoria’s Secret Stock Posts Record Session, Looks to What’s Next

3 June 2026
Victoria’s Secret shares soared 47% to a record $80.06 after a strong quarter and raised 2026 profit outlook, but slipped 2.85% premarket as analysts flagged limited upside after the rally; risks include tariffs, consumer confidence, and an ongoing proxy contest ahead of the June 11 annual meeting.
Dow futures edge lower with oil up, markets watch Wall Street highs

Dow futures edge lower with oil up, markets watch Wall Street highs

3 June 2026
U.S. stock futures were mixed early Wednesday as surging oil prices—Brent up 2.79% to $98.62 and WTI up 3.41% to $96.96—checked Wall Street’s record run, raising inflation fears and casting doubt on further Fed rate cuts, while AI-linked stocks like Marvell jumped 15% in premarket trading after Nvidia’s endorsement.
Go toTop